Most drug targets that fail do so late, after years of work and substantial investment, when effects observed in laboratory or animal models fail to translate to humans. Human genetic evidence offers a way to test that translation directly, revealing how a target is likely to behave in humans before a clinical program begins. AquilaGen exists because this evidence remains underused relative to its demonstrated value. We work to integrate genetic evidence systematically across the R&D cycle, from early target selection through to clinical development.

In practice, this means biotech teams can validate a target before committing years of R&D to it. Pharma teams can stress-test an asset before it absorbs further investment. Investors can de-risk a decision before capital is committed. And CROs can add genetics-grade evidence to the scientific case they deliver to their own clients. Importantly, we collaborate with academia and conduct our own scientific research, allowing us to stay at the forefront of methods and applications of causal inference and genetic epidemiology.

How? We have translated this expertise into a systematic, scalable process. We apply causal inference methods to large-scale genetic and health data, run through Mendelytics™, our proprietary analysis platform built around the paradigm of Mendelian randomization. The result is evidence that goes beyond asking whether a target is associated with disease, to answer the harder question: if you intervene on this target, what happens, to efficacy, to safety, to specific patient subgroups, and to outcomes well beyond the one a programme was originally designed for? We deliver this evidence directly into the decisions that matter, target selection, asset due diligence, and investment committees, in a form your team can act on.